Skip to content

Canadian Cohort on the Origin and Progression of Airway Disease: Physiology Platform

Canadian Cohort on the Origin and Progression of Airway Disease: Physiology Platform

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02153684
Enrollment
99
Registered
2014-06-03
Start date
2015-03-31
Completion date
2022-09-30
Last updated
2024-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD, Smoking

Keywords

smoking, small airway dysfunction, mild COPD, dyspnea, exercise, clinical outcomes

Brief summary

The Canadian Respiratory Research Network (CRRN) has recently been established to study the origins and evolution of airways disease in the population. The CRRN is funded by the Institute of Cardio-respiratory Health (ICRH), an institute of the CIHR. The Physiology platform will support the other CRRN platforms (biology, imaging, population health, knowledge transfer) by providing a comprehensive characterization of the nature and extent of physiological impairment of respiratory function in smokers at risk for airways disease and in those with early or mild airway obstruction. The planned studies of the physiology group (core sites located at Queen's University, University of British Columbia and McGill University) will initially focus on smoking-related lung injury in those at risk for COPD and in those meeting spirometric criteria for mild airway obstruction, with or without respiratory symptoms. The primary aim of this initial study is to identify and validate sensitive test(s) of peripheral airway dysfunction that may qualify as physiological biomarkers for use in future CRRN studies.

Interventions

None listed

Sponsors

Canadian Institutes of Health Research (CIHR)
CollaboratorOTHER_GOV
Ottawa Hospital Research Institute
CollaboratorOTHER
University of British Columbia
CollaboratorOTHER
McGill University
CollaboratorOTHER
Dr. Denis O'Donnell
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

Stable patients with GOLD grade 1 mild COPD will be included in the study if they have: a post-bronchodilator FEV1≥80 %predicted and an FEV1/FVC ratio \<0.7 and \<LLN; ≥40 years of age; and a cigarette smoking history ≥10 pack-years or ≥10 years of exposure to other inhaled substances (i.e., second hand smoke and/or biomass). Symptomatic (category B) subjects will have a Baseline Dyspnea Index (BDI) total score ≤9, a modified Medical Research Council (MRC) dyspnea score ≥2, or a COPD Assessment Test (CAT) score ≥10. Asymptomatic (category A) subjects will have a BDI\>9, modified MRC\<2 or CAT\<10, no history of seeking medical care for respiratory symptoms, and no history of using respiratory medications. Symptomatic current or ex-smokers (\>10 pack-year history) who do not meet criteria for COPD (e.g., post-bronchodilator FEV1\<80%predicted and FEV1/FVC\<0.7, with both measurements also \<LLN) and who are on no respiratory medication will be included. Symptomatic will be defined as: BDI≤9, modified MRC≥2 or CAT\>10. Healthy, age- and sex-matched, non-smoking (\<2 pack-year history) participants with normal spirometry will be used for comparison purposes.

Exclusion criteria

* presence of clinically significant comorbidities that could contribute to dyspnea or exercise limitation (i.e., unstable heart disease, a pulmonary disease other than COPD, uncontrolled diabetes, neuromuscular or orthopedic impairment); * history/clinical evidence of asthma; * contraindications to exercise testing; * \<40 years of age; * body mass index \<18.5 or \>=35 kg/m2.

Design outcomes

Primary

MeasureTime frameDescription
Small airway function1 day (Time of visit)There is no single measurement of small airway function since this study is evaluating which measurements, among a list of conventional and experimental physiological parameters, best characterize the nature and extent of impairment of respiratory function in the smoking study groups and which of these parameters best predict clinical outcome (i.e., dyspnea, exercise capacity, ventilatory capacity, health status). Assessments will include: spirometry, closing volume, impulse oscillometry, frequency dependence of dynamic lung compliance, plethysmographic lung volumes and metronome-paced dynamic hyperinflation.

Secondary

MeasureTime frameDescription
Cardiopulmonary exercise test1 day (Time of visit)Includes measurements of exertional dyspnea (intensity and quality), peak exercise capacity (peak oxygen uptake \[VO2\]) and ventilatory responses (ventilation, pulmonary gas exchange, breathing pattern, operating lung volumes and tidal flow-volume loops) during symptom-limited incremental cardiopulmonary cycle exercise testing.
Clinical outcome1 day (Time of visit)Includes questionnaires regarding chronic activity-related dyspnea, respiratory symptoms, health status and physical activity.

Countries

Canada

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026